Skip to main
RMD
RMD logo

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 55%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is poised for positive financial performance driven by the growing market for respiratory care, underpinned by an increasing diagnosis of sleep apnea and demographic trends such as an aging population and rising obesity rates. The company's revenue from masks and other products in the U.S., Canada, and LATAM has demonstrated a strong year-over-year growth of 12%, indicating robust demand and market share gains in these regions. Furthermore, ResMed's strategy of returning cash to shareholders through increased dividends and an aggressive share repurchase program, while simultaneously investing in operational growth, reflects a strong commitment to enhancing shareholder value amidst anticipated revenue growth.

Bears say

The financial outlook for ResMed is negatively influenced by the potential disruption from GLP-1 drugs, which are expected to impact the future volumes of positive airway pressure (PAP) devices and masks. Despite the company's efforts to differentiate through digital health innovations and its current market outperformance, concerns regarding the impact of GLP-1 drug uptake on growth may hinder revenue growth in the medium term. As ResMed generates a significant portion of its revenues from the Americas, any disruption in key product categories could pose risks to its financial stability and market positioning.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 55% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $297.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $297.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.